The spread of glycopeptide-resistant enterococcal infections across the continental USA has been well documented in the current decade [1, 2] . This expansion has been attributed to the selective pressures associated with extensive use of broad-spectrum antimicrobials (cephalosporins, fluoroquinolones) and vancomycin [l-31. Recent reports of vancomycinresistant enterococci isolated from the feces of poultry or swine and from the carcasses of food animals has intensified the debate concerning the likelihood of these species being a reservoir for pathogens causing both nosocomial and community-acquired infection in humans . The use of glycopeptides and other drugs in western Europe as growth promoters in food animals had been common practice [7, 9] . Earlier studies had demonstrated cross-resistance between veterinary-use glycopeptides (avoparcin) and vancomycin or teicoplanin among enterococci of animal and human origin [5, 10] .
Alexomycin (U-82,127) is an antimicrobial complex that belongs to the cyclic peptide class [ll] . It is a thiopeptide related to the sulfoinycins and is produced by Streptornyces arginensis. The reported spectrum of alexomycin includes Gram-positive pathogens, and the compound has been utilized to promote growth in weanling swine [12] with acceptable results at doses ranging from 3.3 to 55 mg/kg. The most recent investigation determined the most efficacious alexomycin dose range to be between 2.3 and 6.2 mg/kg [lo] . This peptide appears to be a promising candidate to complement or replace other compounds used in animal growth promotion [",lo] , especially those glycopeptides that may select resistant strains thus complicating both animal and human antimicrobial chemotherapy [4] [5] [6] 8, 11, 12] . In this report we summarize the in vitro characterization of alexomycin compared to two glycopeptides, a lipopeptide, selected p-lactams, macrolides, clindamycin, streptogramins, chloramphenicol, fluoroquinolones, and a tetracycline tested against three bacterial groups.
The antimicrobial agents were obtained from the following manufacturers: alexomycin, cefiiofur and clindamycin from Pharmacia Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method [14] , and the interpretive criteria for susceptibility were those published by the National Committee for Clinical Laboratory Standards (NCCLS) [13] . MuellerHinton broth microdilution trays were manufactured by Prepared Media Laboratories (Wilsonville, O R , USA) and stored at -7OOC until used. Quality control strains recommended by the NCCLS (Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212, Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922) were processed concurrently during in vitro susceptibility testing. The alexomycin activity against these strains revealed susceptibility among staphylococci (MICs, 0.12-0.5 mg/L), but resistance in Gram-negative bacilli (MIC, >32 mg/L). Table 1 illustrates the potent activity of alexomycin (MIC range, 0.06-0.5 mg/L) against a selected collection of 42 enterococcal strains. The majority of strains (24) had vanA-, vanB-, vanC1-or vanC2-3-mediated glycopeptide resistances, but remained Vanconiycin resistance was determned by the presence of a vanA, uanB, u a n C~ or uanC2-3 gene as determined by the I'CR t a t . These strains included: Etiteroioccusfaecalis vatiA (two strains) and vanB (thrce strains), E,iterococcLts.fjecirrnr u a d (five strains) and vutiB (fivc strains), Eriterococrus ,qalliriarirrri uanCl (seven strains), and Enteroiocrns cassel$auus iianC2-3 (two strains). None of these strains was from animal sources. Avoparcin was less active than teicoplanin, but was generally more potent than vancomycin, against these enterococci.
Enteritis-associated pathogens, Escherichia coli and Salmonella spp., were also tested, :many strains originating from cultures of humans and various animal species. As expected, the following compounds demonstrated little inhibitory action: alexomycin, avoparcin, teicoplanin, vancomycin, penicillin G, erythromycin A, clindaniycin, and the streptogramin combination. Variable activity was noted for other drugs (53-100% susceptible) with ceftiofur, chloramphenicol and ciprofloxacin inhibiting > 90% of the 80 tested Enterobacteriaceae strains ( Table 2) .
The search for antimicrobial agents that have activity against Gram-positive pathogens has led to structural modifications of existing classes as well as the study of sometimes older cornpounds with unique characteristics, e.g. everninomycin (SCH 27899), glycylcyclines, novobiocin, oxazolidinones, and alexomycin. The potency of alexomycin against vancomycinresistant enterococci was excellent, and cross-resistance with other antimicrobials was not demonstrated among clinical isolates of enterococci. .Also, its spectrum does not include common enteric pathogens from the Enterobacteriaceae. Where glycopeptide-resistant enterococci may have already emerged in the flora of animal species, alexomycin appears to remain a viable alternative as a growth promoter [I 1,121, and no similar agent has been applied to therapy of human infections. This latter fact should limit the potential for interspecies transfer of resistance or the strains having developed genetic factors compromising chemotherapy of important clinical infections.
